News & Events
October 14, 2021
TD2 Partners with Medidata to Enhance its Clinical Operations and Accelerate Clinical Trials
Medidata, a Dassault Systèmes company, today announced that Translational Drug Development (TD2), a precision oncology contract research organization (CRO), has signed an agreement to adopt Medidata’s Rave CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) solutions. Rave CTMS and eTMF are key offerings within Medidata’s Unified Platform, a cutting-edge platform that is transforming the clinical trial experience for patients, sponsors, CROs, and research sites. “TD2 has...
September 16, 2021
TD2 and Deep Lens Partner to Enable Diversity, Access and Faster Clinical Trial Enrollment for Community Oncology Practices
Key Partnership Will Connect Patients with Precision Oncology Clinical Trials and Novel Therapies, Accelerating...
November 24, 2020
Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)
The Companies Plan to Focus On Voltron’s VaxCelerate Vaccine Platform’s Effectiveness and Utility in...
October 29, 2020
TD2 and VieCure Partner to Bring Best-in-Class Cancer Medicines and Access to Precision Oncology Clinical Trials to Patients in Community Oncology Practices
Partnership Will Accelerate the Awareness and Adoption of Precision Oncology in Private Practices and...